Pan-Viral Inhibitor Platform
Multiple Viral Infections (e.g., COVID-19, Influenza)
Pre-clinicalActive
Key Facts
Indication
Multiple Viral Infections (e.g., COVID-19, Influenza)
Phase
Pre-clinical
Status
Active
Company
About AIkido Labs
AIkido Labs Inc. (NASDAQ: AIKI) is a pre-revenue, pre-clinical biotech developer focused on aggregating and advancing early-stage therapeutic assets from top-tier universities. Its core strategy involves securing exclusive worldwide licenses to build a pipeline targeting prostate cancer, pancreatic cancer, AML, ALL, and a pan-viral antiviral platform. The company's primary achievements include establishing key partnerships with institutions like the University of Maryland, Baltimore, The University of Texas, and Wake Forest University, and positioning itself in the public markets to fund its asset development through strategic capital raises.
View full company profile